Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Amikacin for VAP Prophylaxis in Cirrhosis
NCT06808074Phase 4Recruiting
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of amikacin liposome inhalation suspension in ventilator-associated pneumonia (VAP), sponsored by Asian Institute of Gastroenterology. Started Feb 2025; status: recruiting.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT06808074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808074.